Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Other Non-Current Liabilities (2020 - 2022)

Caribou Biosciences has reported Other Non-Current Liabilities over the past 3 years, most recently at $9000.0 for Q1 2022.

  • Quarterly Other Non-Current Liabilities changed N/A to $9000.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $9000.0 through Mar 2022, changed N/A year-over-year, with the annual reading at $17000.0 for FY2021, 90.34% down from the prior year.
  • Other Non-Current Liabilities was $9000.0 for Q1 2022 at Caribou Biosciences, down from $17000.0 in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $176000.0 in Q4 2020 and troughed at $9000.0 in Q1 2022.
  • The 3-year median for Other Non-Current Liabilities is $153000.0 (2021), against an average of $103600.0.
  • The largest YoY upside for Other Non-Current Liabilities was 90.34% in 2021 against a maximum downside of 90.34% in 2021.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $176000.0 in 2020, then tumbled by 90.34% to $17000.0 in 2021, then crashed by 47.06% to $9000.0 in 2022.
  • Per Business Quant, the three most recent readings for CRBU's Other Non-Current Liabilities are $9000.0 (Q1 2022), $17000.0 (Q4 2021), and $153000.0 (Q3 2021).